RCS - MaxCyte, Inc. - MaxCyte and Ori Biotech Announce Collaboration

MaxCyteAnnouncement

11/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nRSK2750Ma&default-theme=true

RNS Number : 2750M  MaxCyte, Inc.  11 June 2025

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and
Broaden Adoption of Autologous Cellular Therapies

 

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO(®)
platforms to improve the yield of gene-edited T cells and shorten
manufacturing timelines

 

 

ROCKVILLE, MD AND LONDON, UK, June 11, 2025  -  MaxCyte, Inc. (Nasdaq: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics, and Oribiotech Ltd.
(https://protect.checkpoint.com/v2/___https:/oribiotech.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplYWU3ZjBjYzI1ZTk3YTFlMmFlMTUzOGQxOTcwMDA2NTo2OjM2N2I6YTVlYjA0OGNiYmFmNDZmZTVkODc1YmY1ODgzZGRiMGExYmJiNDkzOWFlYjJkYTlhMWVhYWNkNmQ3YmViYmI3ODpwOlQ6Rg)
(Ori), a leader in advanced cell and gene therapy (CGT) manufacturing
technology, today announced a strategic collaboration aimed at enhancing
efficiency, scalability, and productivity in cell therapy manufacturing.

 

This collaboration combines the MaxCyte ExPERT(TM) platform and proven Flow
Electroporation(®) technology, widely recognized for its efficient and
scalable transfection capabilities, utilized in over 19 active clinical and
commercial programs, with Ori's innovative next-generation cell therapy
manufacturing platform, IRO(®) (ee-RO). The collaboration will specifically
evaluate how the IRO platform can optimize the yield and streamline the
manufacturing timelines of MaxCyte-engineered primary T cells compared to
traditional post-electroporation cell expansion processes. As a key component
of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via
CRISPR knock-in in activated T cells as the test system for initial
evaluation.

 

MaxCyte's technology offers unparalleled flexibility and efficiency in
transfecting cells at clinical scale, seamlessly integrating with diverse
upstream and downstream processes within cell therapy workflows. The IRO
platform complements this by introducing automated fluid handling,
customizable mixing, and the OriConnect(®) tubeless sterile connection
system, enhancing cell culture efficiency and scalability. Together, these
complementary technologies provide therapy developers with a powerful toolkit
to achieve clinically relevant quantities of gene-edited T cells more rapidly
and efficiently.

 

Maher Masoud, President and CEO of MaxCyte, commented, "We are excited to
collaborate with the team at Ori Biotech, combining our respective strengths
and innovative technologies to significantly enhance manufacturing processes.
This partnership underscores our commitment to enabling therapy developers to
more effectively address the evolving demands of cell therapy manufacturing,
ultimately accelerating the availability of transformative treatments for
patients."

"Our partnership with MaxCyte is another example of Ori's dedication to
providing flexible and scalable solutions that address critical challenges in
cell and gene therapy manufacturing," said Jason C. Foster, CEO of Ori
Biotech. "By integrating modular, best-of-breed technologies, we're raising
the standard of manufacturing by enhancing commercial viability. Ultimately,
this collaboration helps bring cell therapies to patients faster, more
reliably, and at greater scale."

 

Through their shared commitment to innovation and industry collaboration,
MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt
integrated, best-of-breed solutions, accelerating the path from research to
commercialization and making next-generation treatments more accessible to
patients globally.

 

About MaxCyte

At MaxCyte(®), we are committed to building better cells together. As a
leading cell-engineering company, we are driving the discovery, development
and commercialization of next-generation cell therapies. Our best-in-class
Flow Electroporation(®) technology and SeQure DX™ gene editing risk
assessment services enable precise, efficient and scalable cell engineering.
Supported by expert scientific, technical and regulatory guidance, our
platform empowers researchers from around the world to engineer diverse cell
types and payloads, accelerating the development of safe and effective
treatments for human health. For more than 25 years, we've been advancing cell
engineering, shaping the future of medicine. Learn more at maxcyte.com
(https://protect.checkpoint.com/v2/r01/___https:/www.maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo3OWQzNDAwNWRiZTgzNWM3NDY0MmRkNWIyMWRhNjYzMDo3OmU2ZDA6NGU1YzE1NGI0MDg4YzRmYWExNzIwMjM2YzcwY2IwNTMzZjhlZWM4ZGNhNjNlZGViYWU3ZWY1MDM4MWU3MzdkZDpoOlQ6Rg)
 and follow us on X
(https://protect.checkpoint.com/v2/r01/___https:/x.com/maxcyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo3OWQzNDAwNWRiZTgzNWM3NDY0MmRkNWIyMWRhNjYzMDo3OmM0NmM6MTYwZDViNGUyNGIzZWYwMDliNjY5ZDgyMWFmNmRiM2ViMGE4NTM4ODQxYzMyN2U2OGUwZjBjNzhjMzkwZmU1ZTpoOlQ6Rg)
 and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/posts/?feedView=all)

About Ori Biotech

 

Ori Biotech
(https://protect.checkpoint.com/v2/___https:/oribiotech.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplYWU3ZjBjYzI1ZTk3YTFlMmFlMTUzOGQxOTcwMDA2NTo2OjM2N2I6YTVlYjA0OGNiYmFmNDZmZTVkODc1YmY1ODgzZGRiMGExYmJiNDkzOWFlYjJkYTlhMWVhYWNkNmQ3YmViYmI3ODpwOlQ6Rg)
is a London and Philadelphia-based manufacturing technology company on a
mission to enable widespread patient access to life-saving cell and gene
therapies. IRO(®), Ori's next-generation manufacturing platform automates
better biology, accelerates product development and enables therapy developers
to scale their products' clinical and commercial impact by seamlessly
transitioning from R&D to GMP on one platform. The promise of the
innovative Ori platform is to automate cell therapy manufacturing, increasing
throughput, improving quality and decreasing costs by combining proprietary
hardware, consumables, software, data and analytics. For news and updates,
visit oribiotech.com/news-insights.
(https://protect.checkpoint.com/v2/___https:/oribiotech.com/news-insights___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplYWU3ZjBjYzI1ZTk3YTFlMmFlMTUzOGQxOTcwMDA2NTo2OjM0MjM6Zjk5ODBlNGE4ZWRkZTAwZDFkMzBmNmVkMTMxODUzZjcxNDVlYzNkMWQxOGEwNTJhYmI2YjEyYWM4NjYxM2U0NTpwOlQ6Rg)

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the anticipated
benefits, outcomes, and impact of the collaboration between MaxCyte and Ori
Biotech; the potential for improving clinical success and commercial viability
through new manufacturing standards; and the intention to accelerate
development timelines, increase access to next-generation cell therapies, and
deliver transformative treatments to patients globally.
 

These statements are based on current expectations, estimates, forecasts, and
projections about the industry and markets in which MaxCyte operates, as well
as management's current beliefs and assumptions. Words such as "aims,"
"expects," "anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "may," "will," "should," "continue," and variations of such words
and similar expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and involve certain
risks, uncertainties, and assumptions that are difficult to predict and are
often beyond the control of the companies involved.  Actual outcomes and
results may differ materially from those expressed or implied in these
forward-looking statements due to various factors, including changes in market
conditions, technological advancements, regulatory developments, and the
success of ongoing research and evaluation efforts.
 

Risks and uncertainties related to our business are described in greater
detail in Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2024, filed with the Securities and Exchange Commission ("SEC")
on March 11, 2025, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings that we make
with the Securities and Exchange Commission from time to time, including in
our Form 10-Q for the quarter ended May 8, 2025. These documents are available
through the Investor Menu, Financials section, under "SEC Filings" on the
Investors page of our website at http://investors.maxcyte.com
(https://protect.checkpoint.com/v2/___http:/investors.maxcyte.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplYWU3ZjBjYzI1ZTk3YTFlMmFlMTUzOGQxOTcwMDA2NTo2OmM4NTc6YTI3ZWFlMjlmZTQzYTRiNzU4YzUyMTBhNjQwMzc4ZTc0ZmMxZDA1NjA0MmVmNjU1ZWZjNDQzYTU2ZmI0NWNmZTpwOlQ6Rg)
.

Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Except as
required by law, MaxCyte does not undertake any obligation to update or revise
any forward-looking statements to reflect new information, events, or
circumstances after the date of this release.

 

 

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400
ir@maxcyte.com (mailto:ir@maxcyte.com)

Oak Street Communications

Kristen White
kristen@oakstreetcommunications.com
(mailto:kristen@oakstreetcommunications.com)

415.608.6060

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700
maxcyte@icrhealthcare.com (mailto:maxcyte@icrhealthcare.com)

Ori Biotech Contact:

Debby Betz
media@oribiotech.com (mailto:media@oribiotech.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKKEFENSEFA